Evidence map›Paper›PMID 40849252›Full record

ReviewBlood reviews2025

DecodingAcute GVHD: The role of serum biomarkers and imaging in diagnosis and management.

Rohit Singh, Happy Agarwal, Ryan Bynum, Eli J Isenberg, Mary Erdmann, Joshua Glover, Molly McNally, Jorge Gomez-Gutierrez, Lacey McNally, Jennifer Holter-Chakrabarty

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rohit SinghStephenson Cancer Center, Department of Surgery, University of Oklahoma, Oklahoma City, OK 73104, USA. Electronic address: Rohit-Singh@ouhsc.edu.
Happy AgarwalStephenson Cancer Center, Department of Surgery, University of Oklahoma, Oklahoma City, OK 73104, USA. Electronic address: Happy-Agarwal@ouhsc.edu.
Ryan BynumStephenson Cancer Center, Department of Surgery, University of Oklahoma, Oklahoma City, OK 73104, USA. Electronic address: Ryan-Bynum@ouhsc.edu.
Eli J IsenbergHealth Science Center, Department of Medicine, University of Oklahoma, Oklahoma City, OK 73104, USA. Electronic address: eli-isenberg@ouhsc.edu.
Mary ErdmannHealth Science Center, Department of Medicine, University of Oklahoma, Oklahoma City, OK 73104, USA. Electronic address: mary-erdmann@ouhsc.edu.
Joshua GloverHealth Science Center, Department of Medicine, University of Oklahoma, Oklahoma City, OK 73104, USA. Electronic address: joshua-glover@ouhsc.edu.
Molly McNallyStephenson Cancer Center, Department of Surgery, University of Oklahoma, Oklahoma City, OK 73104, USA.
Jorge Gomez-GutierrezDepartment of Pediatrics, University of Missouri, MO, USA.
Lacey McNallyStephenson Cancer Center, Department of Surgery, University of Oklahoma, Oklahoma City, OK 73104, USA. Electronic address: lacey-mcnally@ouhsc.edu.
Jennifer Holter-ChakrabartyHealth Science Center, Department of Medicine, University of Oklahoma, Oklahoma City, OK 73104, USA. Electronic address: jholter2@ouhsc.edu.

Funding

Imaging and Blood Biomarkers to Predict Graft Failure after HSCTR01HL146668 · NHLBI · EMORY UNIVERSITY · PI HOLTER CHAKRABARTY, JENNIFER LIN, WILLIAMS, KIRSTEN · 2019 to 2023
$2.9M
Bioengineering probiotic bacterium contrast agents for monitoring of inflammation using multispectral optoacoustic tomographyR01EB033919 · NIBIB · UNIVERSITY OF MISSOURI-COLUMBIA · PI GOMEZ-GUTIERREZ, JORGE G · 2024 to 2024
$470k
Non-invasive assessment of graft vs host disease using optoacoustic imagingR21CA271218 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HOLTER CHAKRABARTY, JENNIFER LIN, MCNALLY, LACEY R · 2023 to 2024
$363k
NCI NIH HHS R21 CA271218NHLBI NIH HHS R01 HL146668NIBIB NIH HHS R01 EB033919
6 · The paper itself

Abstract

Graft-versus-host disease (GVHD) is one of the major barriers to the clinical success of hematopoietic stem cell transplantation (HCT). Despite improvements in GVHD incidence with the use of post-transplant cyclophosphamide, cord blood transplantation, and improvement in donor identification and matching, it remains a major cause of death in HCT. Early and accurate identification of GVHD is required to improve HCT outcomes. Diagnosis ambiguity continues to be problematic, despite improvements in PCR based stool studies, immunohistochemical markers in tissue biopsy, and improvement in histopathological examination. Unfortunately, therefore, early diagnosis of GVHD suffers from the lack of established diagnostic biomarkers which could improve prompt identification and treatment of GVHD at a time when therapeutic outcome is most impactful. This review discusses available diagnostic serum biomarkers and imaging advancements available to predict onset, severity, and prognosis in GVHD. Additionally, this review highlights the differential diagnosis of GVHD from other related pathological conditions.

Indexed as

BiomarkersDiagnostic ImagingGraft vs Host DiseaseAcute DiseaseDisease ManagementHematopoietic Stem Cell TransplantationHumansPrognosisBiomarkersBiomarkerDiagnosisGraft versus host diseaseImagingPathophysiology

Identifiers

PMID40849252
PMCPMC12483143

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.